Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatitis C Virus Genetic Variability and the Presence of NS5B Resistance-Associated Mutations as Natural Polymorphisms in Selected Genotypes Could Affect the Response to NS5B Inhibitors
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 5, Pages 2781-2797
Publisher
American Society for Microbiology
Online
2014-03-04
DOI
10.1128/aac.02386-13
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C
- (2013) Dominique Larrey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy
- (2013) Valeria Cento et al. ANTIVIRAL THERAPY
- Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage
- (2013) Mengjie Chen et al. BIOINFORMATICS
- Hepatitis C virus therapy update 2013
- (2013) Lisa C. Casey et al. CURRENT OPINION IN GASTROENTEROLOGY
- RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs
- (2013) Yasir Waheed et al. INFECTION GENETICS AND EVOLUTION
- Interferon free regimens for the “difficult-to-treat”: Are we there?
- (2013) Maria-Carlota Londoño et al. JOURNAL OF HEPATOLOGY
- The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from theLos Alamosdatabank
- (2013) R. Alves et al. JOURNAL OF VIRAL HEPATITIS
- Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
- (2013) Troels K H Scheel et al. NATURE MEDICINE
- Novel therapies for hepatitis C — one pill fits all?
- (2013) Michael P. Manns et al. NATURE REVIEWS DRUG DISCOVERY
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- TMC647055, a Potent Nonnucleoside Hepatitis C Virus NS5B Polymerase Inhibitor with Cross-Genotypic Coverage
- (2012) Benoit Devogelaere et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase
- (2012) M. Fenaux et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral resistance and direct-acting antiviral agents for HCV
- (2012) Amanda L Aloia et al. ANTIVIRAL THERAPY
- Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase
- (2012) Jean-Michel Pawlotsky et al. ANTIVIRAL THERAPY
- The role of resistance in HCV treatment
- (2012) Johannes Vermehren et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- The Polymorphisms of DNA G-Quadruplex Investigated by Docking Experiments with Telomestatin Enantiomers
- (2012) Stefano Alcaro et al. CURRENT PHARMACEUTICAL DESIGN
- Drug resistance testing in hepatitis C therapy
- (2012) Eva Poveda et al. Future Virology
- Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of HCV NS5B Protein. [10.5812/hepatmon.6142]
- (2012) Yasir Waheed et al. Hepatitis Monthly
- Antiviral strategies in hepatitis C virus infection
- (2012) Christoph Sarrazin et al. JOURNAL OF HEPATOLOGY
- 1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN
- (2012) D. McPhee et al. JOURNAL OF HEPATOLOGY
- Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
- (2012) Dominique Larrey et al. JOURNAL OF HEPATOLOGY
- 1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- Perspectives and challenges of interferon-free therapy for chronic hepatitis C
- (2012) Christian M. Lange et al. JOURNAL OF HEPATOLOGY
- Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
- (2012) Doug J. Bartels et al. JOURNAL OF VIROLOGY
- HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
- (2012) Valeria Cento et al. PLoS One
- The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance
- (2012) Matthias Götte Current Opinion in Virology
- Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
- (2012) Ruy M. Ribeiro et al. PLoS Pathogens
- Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2011) I-hung Shih et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients
- (2011) Philip J. F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Investigation of the mode of binding of a novel series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides to the hepatitis C virus polymerase
- (2011) Robert G. Gentles et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine
- (2011) Stefano Alcaro et al. ChemMedChem
- Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development
- (2011) Valentina Svicher et al. DIGESTIVE AND LIVER DISEASE
- Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B
- (2011) Simona Distinto et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
- (2011) Jean-Michel Pawlotsky HEPATOLOGY
- Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients
- (2011) Z. Plaza et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 1211 EMERGENCE AND PERSISTENCE OF NS5B MUTATIONS FOLLOWING COMBINATION TREATMENT WITH TEGOBUVIR (GS-9190) PLUS STANDARD OF CARE-LONG-TERM FOLLOW-UP FROM THE PHASE IIB STUDY GS-US-196-0103
- (2011) C. Hebner et al. JOURNAL OF HEPATOLOGY
- 1225 CHARACTERIZATION OF VIRAL RESISTANCE MUTATIONS IN GENOTYPE 1 HCV PATIENTS RECEIVING COMBINATION THERAPY WITH A PROTEASE INHIBITOR AND A POLYMERASE INHIBITOR WITH OR WITHOUT RIBAVIRIN
- (2011) H. Mo et al. JOURNAL OF HEPATOLOGY
- Chromone, a Privileged Scaffold for the Development of Monoamine Oxidase Inhibitors
- (2011) Alexandra Gaspar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
- (2011) Philippe Halfon et al. LIVER INTERNATIONAL
- An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region
- (2011) Tatsunori Nakano et al. LIVER INTERNATIONAL
- MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods
- (2011) K. Tamura et al. MOLECULAR BIOLOGY AND EVOLUTION
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
- (2011) M. H. Powdrill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rational Design, Synthesis, Biophysical and Antiproliferative Evaluation of Fluorenone Derivatives with DNA G-Quadruplex Binding Properties
- (2010) Stefano Alcaro et al. ChemMedChem
- Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors
- (2010) Rossella Fioravanti et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 762 RESISTANCE PROFILE OF ABT-333 AND RELATIONSHIP TO VIRAL LOAD DECREASE IN PATIENTS TREATED IN COMBINATION WITH PEG-INTERFERON AND RIBAVIRIN FOR 28 DAYS
- (2010) T. Middleton et al. JOURNAL OF HEPATOLOGY
- A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
- (2010) Bambang S. Adiwijaya et al. PLoS Computational Biology
- Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus
- (2009) R. A. Love et al. JOURNAL OF VIROLOGY
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
- (2008) S. Ali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
- (2008) Silvana Gaudieri et al. HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
- Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects
- (2008) Doug J. Bartels et al. JOURNAL OF INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started